Afamelanotide (Scenesse): The Approved Melanocortin Agonist

Afamelanotide, marketed as Scenesse and historically known as Melanotan I, is an FDA-approved alpha-MSH analog. Its approval is instructive precisely because a closely related compound — Melanotan II — remains unapproved and widely misused. The difference between them is a case study in what approval requires.

This guide situates Afamelanotide within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

What erythropoietic protoporphyria is

EPP is a rare inherited disorder of heme synthesis in which protoporphyrin IX accumulates in the skin. Protoporphyrin absorbs light energy and generates reactive oxygen species, so sunlight causes severe phototoxic pain — often described as intense burning — sometimes within minutes of exposure and lasting for days.

Crucially, this is not a rash and not a sunburn. It is pain, frequently with little visible change, which historically led to patients being disbelieved.

The consequences are severe. Patients with EPP live restricted lives, avoiding daylight, with substantial effects on employment, education and mental health. Before afamelanotide there was no effective treatment beyond strict light avoidance.

How afamelanotide works

Afamelanotide is an alpha-MSH analog that activates MC1R on melanocytes, increasing production of eumelanin. Eumelanin absorbs and dissipates light energy, providing photoprotection independent of ultraviolet-induced tanning.

For an EPP patient, that added photoprotection means more time in light before pain begins — the endpoint the pivotal trials measured, and the outcome that changes daily life.

It is delivered as a bioresorbable implant inserted subcutaneously by a trained healthcare professional, releasing drug over a period of months. That delivery choice is deliberate: it produces controlled, sustained exposure administered under supervision, rather than self-injection of an unregulated product at whatever frequency a user chooses.

What separates this from Melanotan II

The comparison is the reason this guide matters. Afamelanotide and Melanotan II are related alpha-MSH analogs producing overlapping pigmentary effects. One is approved; one is not. The difference is instructive.

Afamelanotide had a defined medical indication in a serious condition with genuine unmet need. It underwent controlled clinical trials with pre-specified endpoints. Its manufacturing is regulated for identity, purity and dose. Its delivery is controlled and clinician-administered. And it carries specified monitoring requirements — notably regular skin examination, because a drug stimulating melanocytes warrants dermatologic surveillance.

Melanotan II has none of that. It is used for cosmetic tanning, self-administered at unregulated doses from unverified material, without medical oversight or skin monitoring.

The lesson generalizes across this whole formulary: the difference between a medicine and a research chemical is rarely the molecule. It is the indication, the evidence, the manufacturing, the delivery and the supervision.

Practical considerations

Afamelanotide is not approved for cosmetic tanning and is not available for that purpose. Its indication is narrow, its distribution is controlled, and it is administered through specialist centres by trained providers.

Reported adverse effects include implant site reactions, nausea, headache and fatigue. Because it stimulates melanocytes, twice-yearly skin examination is part of appropriate care, and pre-existing melanocytic lesions warrant baseline assessment.

For clinicians, this is also worth knowing as a diagnostic prompt. A patient describing severe burning pain from sun exposure without an obvious rash — particularly since childhood — may have an undiagnosed porphyria, and that possibility is frequently missed for years.